• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗病毒治疗对乙型肝炎/丙型肝炎相关死亡率和纤维化消退影响的综述。

Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis.

机构信息

Comprehensive Digestive Institute of Nevada, Las Vegas, NV 89148, USA.

出版信息

Viruses. 2024 Sep 27;16(10):1531. doi: 10.3390/v16101531.

DOI:10.3390/v16101531
PMID:39459866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512229/
Abstract

Hepatitis B and Hepatitis C are viral causes of Hepatitis that lead to significant worldwide mortality and morbidity through the sequelae of fibrosis and hepatocellular carcinoma. In this review, we have summarized recent studies that have examined the effects of antiviral therapy on the regression of fibrosis and the reduction in mortalities associated with the viruses. Antiviral therapy significantly decreases mortality and induces the regression of fibrosis.

摘要

乙型肝炎和丙型肝炎是导致肝炎的病毒病因，通过纤维化和肝细胞癌的后遗症导致全球范围内大量的死亡率和发病率。在这篇综述中，我们总结了最近研究检查抗病毒治疗对纤维化的逆转和与病毒相关的死亡率降低的影响。抗病毒治疗可显著降低死亡率并诱导纤维化的逆转。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/fb0f84842acb/viruses-16-01531-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/dd351391dd8c/viruses-16-01531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/c2a923afd0a7/viruses-16-01531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/fb0f84842acb/viruses-16-01531-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/dd351391dd8c/viruses-16-01531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/c2a923afd0a7/viruses-16-01531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef9f/11512229/fb0f84842acb/viruses-16-01531-g003.jpg

相似文献

1
Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis.抗病毒治疗对乙型肝炎/丙型肝炎相关死亡率和纤维化消退影响的综述。
Viruses. 2024 Sep 27;16(10):1531. doi: 10.3390/v16101531.
2
Surveillance of HIV and viral hepatitis by analysis of samples from drug related deaths.
Eur J Epidemiol. 2006;21(5):383-7. doi: 10.1007/s10654-006-9009-x. Epub 2006 Jun 9.
3
Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.抗病毒治疗对慢性乙型肝炎和肝硬化患者的影响。
Expert Rev Gastroenterol Hepatol. 2017 Dec;11(12):1095-1104. doi: 10.1080/17474124.2017.1361822. Epub 2017 Aug 7.
4
Liver Fibrosis Reversion After Suppression of Hepatitis B Virus.乙型肝炎病毒抑制后肝纤维化的逆转
Clin Liver Dis. 2016 Nov;20(4):667-679. doi: 10.1016/j.cld.2016.06.003.
5
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.乙型肝炎病毒/丙型肝炎病毒合并感染的治疗进展
Expert Opin Pharmacother. 2014 Jul;15(10):1337-49. doi: 10.1517/14656566.2014.913571. Epub 2014 Apr 29.
6
The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.乙肝病毒载量会降低免疫检查点抑制剂对肝细胞癌患者的疗效。
Front Immunol. 2024 Nov 27;15:1480520. doi: 10.3389/fimmu.2024.1480520. eCollection 2024.
7
Treatment of HBV-related cirrhosis.乙肝相关肝硬化的治疗
Expert Rev Anti Infect Ther. 2009 Jun;7(5):527-35. doi: 10.1586/eri.09.28.
8
De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.拉米夫定和阿德福韦酯联合治疗与恩替卡韦单药治疗乙型肝炎病毒相关失代偿期肝硬化的疗效比较。
World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.
9
Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.乙型肝炎病毒相关性肝移植：适应证减少及趋势变化
World J Gastroenterol. 2015 Jul 14;21(26):8140-7. doi: 10.3748/wjg.v21.i26.8140.
10
Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.直接作用抗病毒药物治疗的乙型肝炎和丙型肝炎合并感染者的肝纤维化进展和死亡率：来自 ERCHIVES 的结果。
Clin Infect Dis. 2020 Jul 27;71(3):664-666. doi: 10.1093/cid/ciz1097.

引用本文的文献

1
Changing trends in upper gastrointestinal endoscopic findings in Ethiopia: A comparison of eighteen thousand exams across two periods.埃塞俄比亚上消化道内镜检查结果的变化趋势：两个时期内一万八千例检查的比较。
World J Gastrointest Endosc. 2025 May 16;17(5):106690. doi: 10.4253/wjge.v17.i5.106690.
2
Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation.西班牙病毒性肝炎的综合诊断：实施依据
Viruses. 2025 May 3;17(5):667. doi: 10.3390/v17050667.
3
Role of etiological therapy in achieving recompensation of decompensated liver cirrhosis.

本文引用的文献

1
Extrahepatic Malignancies Are the Leading Cause of Death in Patients with Chronic Hepatitis B without Cirrhosis: A Large Population-Based Cohort Study.肝外恶性肿瘤是慢性乙型肝炎非肝硬化患者的主要死因：一项基于大人群的队列研究
Cancers (Basel). 2024 Feb 7;16(4):711. doi: 10.3390/cancers16040711.
2
Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.使用直接作用抗病毒药物治疗丙型肝炎病毒对降低与肝外表现相关的死亡率的影响：加拿大不列颠哥伦比亚省一项基于人群的大型研究。
Lancet Reg Health Am. 2023 Dec 29;29:100658. doi: 10.1016/j.lana.2023.100658. eCollection 2024 Jan.
3
病因治疗在实现失代偿期肝硬化代偿中的作用。
World J Hepatol. 2025 Apr 27;17(4):105127. doi: 10.4254/wjh.v17.i4.105127.
Long-Term Survival and Cancer Risk in the Hepatitis C Virus-Infected Patients After Antiviral Treatment: A Nationwide Cohort Study.
抗病毒治疗后丙型肝炎病毒感染患者的长期生存及癌症风险：一项全国性队列研究
J Cancer. 2024 Jan 1;15(1):113-125. doi: 10.7150/jca.87259. eCollection 2024.
4
Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents.接受直接抗病毒药物治疗的丙型肝炎病毒患者的肝纤维化消退及相关因素
Life (Basel). 2023 Sep 5;13(9):1872. doi: 10.3390/life13091872.
5
The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.P-I-R 分类在预测乙型肝炎和晚期肝纤维化患者治疗过程中的组织学和临床结局中的应用。
Hepatology. 2024 Feb 1;79(2):425-437. doi: 10.1097/HEP.0000000000000563. Epub 2023 Aug 23.
6
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.在无干扰素抗病毒药物时代成功治疗丙型肝炎患者的死亡率：基于人群的队列研究。
BMJ. 2023 Aug 2;382:e074001. doi: 10.1136/bmj-2022-074001.
7
Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B.抗病毒治疗期间纤维化-4 改善与乙型肝炎肝硬化患者肝癌风险降低相关。
Sci Rep. 2023 Jun 9;13(1):9443. doi: 10.1038/s41598-023-36668-2.
8
Insights into the impact of hepatitis B virus on hepatic stellate cell activation.乙型肝炎病毒对肝星状细胞激活影响的研究进展
Cell Commun Signal. 2023 Apr 11;21(1):70. doi: 10.1186/s12964-023-01091-7.
9
Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.老年丙型肝炎患者接受直接作用抗病毒治疗后肝纤维化消退。
BMC Gastroenterol. 2023 Apr 3;23(1):102. doi: 10.1186/s12876-023-02732-4.
10
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm.慢性乙型肝炎患者核苷（酸）类似物停药的安全性考虑：一、不造成伤害。
Clin Mol Hepatol. 2023 Oct;29(4):869-890. doi: 10.3350/cmh.2022.0420. Epub 2023 Mar 14.